Friday, July 10, 2026
🇺🇸 FDA

pharma · Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) · Advanced Solid Tumor

Daiichi Sankyo US

Daiichi Sankyo

Daiichi Sankyo US drug portfolio — 66 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Website Investor relations
211 Mt. Airy Road Basking Ridge, Basking Ridge, NJ 07920, US HQ
4,386 Employees
NMPA registrant Type
Company details
Status
Public
HQ
211 Mt. Airy Road Basking Ridge, Basking Ridge, NJ 07920, US
Employees
4,386
Programs
58
Drugs
66
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Drug Pipeline

Daiichi Sankyo US pipeline

Portfolio lens on 66 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Daiichi Sankyo US drug portfolio — 66 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

66 compounds

  1. atezolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 inhibitor

  2. atorvastatin

    Development asset linked to Daiichi Sankyo US in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.

    Mechanism
    HMG-CoA reductase inhibitor

  3. bempedoic acid

    Cardiovascular system (C10)

    US regulatory status: approved. Molecular target: ATP-citrate synthase.

    Target
    ATP-citrate synthase
    Mechanism
    ATP-citrate synthase inhibitor

  5. bevacizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.

    Target
    Vascular endothelial growth factor A, long form
    Mechanism
    Vascular endothelial growth factor A inhibitor

  6. capecitabine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  7. carboplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  8. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  9. chemotherapy

    Development asset linked to Daiichi Sankyo US in public FDA and regional records.

  10. chloride

    Development asset linked to Daiichi Sankyo US in public FDA and regional records.

  11. cisplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  12. combination

    Development asset linked to Daiichi Sankyo US in public FDA and regional records.

  15. darolutamide

    Antineoplastic and immunomodulating agents (L02)

    US regulatory status: approved. Molecular target: Androgen receptor.

    Target
    Androgen receptor
    Mechanism
    Androgen Receptor antagonist

  16. dato-dxd

    Development asset linked to Daiichi Sankyo US in public FDA and regional records. Molecular target: DNA topoisomerase 1.

    Target
    DNA topoisomerase 1
    Mechanism
    DNA topoisomerase I inhibitor

  17. datopotamab deruxtecan

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Daiichi Sankyo US's portfolio. Molecular target: DNA topoisomerase 1.

    Target
    DNA topoisomerase 1
    Mechanism
    Tumor-associated calcium signal transducer 2 binding agent

  19. docetaxel

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  20. doxorubicin

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Daiichi Sankyo US's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.

    Mechanism
    DNA topoisomerase II alpha inhibitor

  21. doxorubicin hydrochloride

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA topoisomerase II alpha inhibitor

  22. edoxaban

    Blood and blood forming organs (B01)

    US regulatory status: approved. Mechanism: Coagulation factor X inhibitor.

    Mechanism
    Coagulation factor X inhibitor

  23. edoxaban tosylate

    US regulatory status: approved. Molecular target: Coagulation factor X.

    Target
    Coagulation factor X
    Mechanism
    Coagulation factor X inhibitor

  24. epcoritamab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Daiichi Sankyo US's portfolio. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  25. etoposide

    US regulatory status: approved. Molecular target: DNA topoisomerase II.

    Target
    DNA topoisomerase II
    Mechanism
    DNA topoisomerase II inhibitor

  26. ezetimibe

    US regulatory status: approved. Molecular target: NPC1-like intracellular cholesterol transporter 1.

    Target
    NPC1-like intracellular cholesterol transporter 1
    Mechanism
    Niemann-Pick C1-like protein 1 inhibitor

  27. fluorouracil

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  28. hema-

    Development asset linked to Daiichi Sankyo US in public FDA and regional records.

  29. hydromorphone

    Development asset linked to Daiichi Sankyo US in public FDA and regional records. Mechanism: Mu opioid receptor agonist.

    Mechanism
    Mu opioid receptor agonist

  30. idarubicin

    Development asset linked to Daiichi Sankyo US in public FDA and regional records. Mechanism: DNA topoisomerase II alpha inhibitor.

    Mechanism
    DNA topoisomerase II alpha inhibitor

  31. individual

    Development asset linked to Daiichi Sankyo US in public FDA and regional records.

  32. infusion

    Development asset linked to Daiichi Sankyo US in public FDA and regional records.

  33. irinotecan

    Development asset linked to Daiichi Sankyo US in public FDA and regional records. Mechanism: DNA topoisomerase I inhibitor.

    Mechanism
    DNA topoisomerase I inhibitor

  34. irinotecan hydrochloride

    US regulatory status: approved. Molecular target: DNA topoisomerase 1.

    Target
    DNA topoisomerase 1
    Mechanism
    DNA topoisomerase I inhibitor

  35. matching

    Development asset linked to Daiichi Sankyo US in public FDA and regional records.

  36. olmesartan

    Development asset linked to Daiichi Sankyo US in public FDA and regional records. Molecular target: Type-1 angiotensin II receptor.

    Target
    Type-1 angiotensin II receptor
    Mechanism
    Type-1 angiotensin II receptor antagonist

  37. olmesartan medoxomil

    US regulatory status: approved. Molecular target: Type-1 angiotensin II receptor.

    Target
    Type-1 angiotensin II receptor
    Mechanism
    Type-1 angiotensin II receptor antagonist

  38. oxaliplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  39. paclitaxel

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  40. pembrolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  41. pemetrexed sodium

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  42. penicillamine

    US regulatory status: approved. Molecular target: Copper.

    Target
    Copper
    Mechanism
    Copper chelating agent

  43. peritoneal

    Development asset linked to Daiichi Sankyo US in public FDA and regional records.

  44. placebo

    Development asset linked to Daiichi Sankyo US in public FDA and regional records.

  45. powder

    Development asset linked to Daiichi Sankyo US in public FDA and regional records.

  46. protocol

    Development asset linked to Daiichi Sankyo US in public FDA and regional records.

  47. quizartinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Daiichi Sankyo US's portfolio. Molecular target: Macrophage colony-stimulating factor 1 receptor.

    Target
    Macrophage colony-stimulating factor 1 receptor
    Mechanism
    Platelet-derived growth factor receptor inhibitor

  48. ramucirumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor 2.

    Target
    Vascular endothelial growth factor receptor 2
    Mechanism
    Vascular endothelial growth factor receptor 2 inhibitor

  49. rituximab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  50. rizatriptan

    Development asset linked to Daiichi Sankyo US in public FDA and regional records. Mechanism: Serotonin 1b (5-HT1b) receptor agonist.

    Mechanism
    Serotonin 1b (5-HT1b) receptor agonist

  51. rosuvastatin

    Development asset linked to Daiichi Sankyo US in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.

    Mechanism
    HMG-CoA reductase inhibitor

  52. solution

    Development asset linked to Daiichi Sankyo US in public FDA and regional records.

  53. statin

    Development asset linked to Daiichi Sankyo US in public FDA and regional records.

  54. stro-

    Development asset linked to Daiichi Sankyo US in public FDA and regional records.

  55. subcutaneous

    Development asset linked to Daiichi Sankyo US in public FDA and regional records.

  56. tablet

    Development asset linked to Daiichi Sankyo US in public FDA and regional records.

  57. tablets

    Development asset linked to Daiichi Sankyo US in public FDA and regional records.

  58. therapy

    Development asset linked to Daiichi Sankyo US in public FDA and regional records.

  59. topotecan

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Daiichi Sankyo US's portfolio. Mechanism: DNA topoisomerase I, mitochondrial inhibitor.

    Mechanism
    DNA topoisomerase I, mitochondrial inhibitor

  60. topotecan hydrochloride

    US regulatory status: approved. Molecular target: DNA topoisomerase 1.

    Target
    DNA topoisomerase 1
    Mechanism
    DNA topoisomerase I, mitochondrial inhibitor

  61. trastuzumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.

    Target
    Receptor tyrosine-protein kinase erbB-2
    Mechanism
    Receptor protein-tyrosine kinase erbB-2 inhibitor

  62. trastuzumab deruxtecan

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Daiichi Sankyo US's portfolio. Molecular target: DNA topoisomerase 1.

    Target
    DNA topoisomerase 1
    Mechanism
    DNA topoisomerase I inhibitor

  63. trastuzumab emtansine

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Daiichi Sankyo US's portfolio. Molecular target: Receptor tyrosine-protein kinase erbB-2.

    Target
    Receptor tyrosine-protein kinase erbB-2
    Mechanism
    Tubulin inhibitor

  64. trastuzumab-pkrb

    US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.

    Target
    Receptor tyrosine-protein kinase erbB-2
    Mechanism
    Receptor protein-tyrosine kinase erbB-2 inhibitor

  65. treatment

    Development asset linked to Daiichi Sankyo US in public FDA and regional records.

  66. valemetostat tosilate

    Development asset linked to Daiichi Sankyo US in public FDA and regional records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.